Physician profile
Grace Nesper
NPI 1073063483
$7,174.28
in general payments reported to CMS, 2019-2025
34 companies · $980 in 2025
The $980 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,494 · 2022: $1,381 · 2023: $1,274 · 2024: $2,046 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,299.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,323.35 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $759.42 | 2021-2025 | Ajovy, Austedo Xr |
| Currax Pharmaceuticals LLC | $685.00 | 2021-2024 | Onzetra Xsail, Contrave |
| Biohaven Pharmaceuticals, INC. | $611.77 | 2021 | |
| Pfizer INC. | $557.98 | 2023-2025 | |
| Amgen INC. | $411.76 | 2021-2024 | Aimovig |
| Lilly USA, LLC | $411.74 | 2022-2025 | Emgality, Reyvow, Zepbound |
| Impel Pharmaceuticals INC. | $275.99 | 2023 | Trudhesa |
| Lundbeck LLC | $225.97 | 2023-2025 | Vyepti |
| Tonix Medicines, INC. | $222.97 | 2024-2025 | Zembrace Symtouch |
| Biohaven Pharmaceutical Holding Company Ltd. | $199.17 | 2022 | |
| Eisai INC. | $174.98 | 2024-2025 | |
| Impel Pharmaceuticals LLC | $114.23 | 2024-2025 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $104.54 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $100.88 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $97.14 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $91.45 | 2024 | |
| Ucb, INC. | $91.05 | 2023-2024 | Nayzilam |
| Averitas Pharma INC. | $80.39 | 2024-2025 | Qutenza |
| Novo Nordisk INC | $67.59 | 2024-2025 | Wegovy |
| Springworks Therapeutics, INC. | $58.81 | 2025 | Gomekli |
| Ge Healthcare | $57.24 | 2021-2023 | |
| Catalyst Pharmaceuticals, INC. | $56.95 | 2022-2023 | Firdapse |
| Novartis Pharmaceuticals Corporation | $53.92 | 2021 | |
| Ibsa Pharma INC. | $52.83 | 2024-2025 | Licart, Tirosint, Flector |
| Axsome Therapeutics, INC. | $48.57 | 2025 | Symbravo |
| Amneal Pharmaceuticals LLC | $45.37 | 2024-2025 | Brekiya, Avastin |
| Jazz Pharmaceuticals INC. | $43.40 | 2022-2024 | |
| Boston Scientific Corporation | $30.32 | 2023 | Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $29.88 | 2023 | Nuedexta |
| Novocure INC. | $26.38 | 2021-2022 | |
| Octapharma USA, INC. | $24.79 | 2024 | Panzyga |
| Adamas Pharmaceuticals, INC. | $23.91 | 2021 | |
| Allergan, INC. | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Nesper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.